Development of Dry Powder Inhaler Patient Interfaces for Improved Aerosol Delivery to Children

Overview

Journal AAPS PharmSciTech

Publisher Springer

Specialty Pharmacology

Date 2020 May 27

PMID 32451773

Citations 10

Authors

Karl Bass

Worth Longest

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to explore different internal flow passages in the patient interface region of a new air-jet-based dry powder inhaler (DPI) in order to minimize device and extrathoracic aerosol depositional losses using computational fluid dynamics (CFD) simulations. The best-performing flow passages were used for oral and nose-to-lung (N2L) aerosol delivery in pediatric extrathoracic airway geometries consistent with a 5-year-old child. Aerosol delivery conditions were based on a previously developed and tested air-jet DPI device and included a base flow rate of 13.3 LPM (delivered from a small ventilation bag) and an inhaled air volume of 750 mL. Initial CFD models of the system clearly established that deposition on either the back of the throat or nasal cannula bifurcation was strongly correlated with the maximum velocity exiting the flow passage. Of all designs tested, the combination of a 3D rod array and rapid expansion of the flow passage side walls was found to dramatically reduce interface and device deposition and improve lung delivery of the aerosol. For oral aerosol administration, the optimal flow passage compared with a base case reduced device, mouthpiece, and mouth-throat deposition efficiencies by factors of 8-, 3-, and 2-fold, respectively. For N2L aerosol administration, the optimal flow pathway compared with a base case reduced device, nasal cannula, and nose-throat deposition by 16-, 6-, and 1.3-fold, respectively. In conclusion, a new patient interface design including a 3D rod array and rapid expansion dramatically improved transmission efficiency of a dry powder aerosol.

Citing Articles

Development of an Infant Air-Jet Dry Powder Aerosol Delivery System (iDP-ADS) Including a New Multifunctional Bifurcating Two-Prong Nasal Interface.

Strickler S, Farkas D, Momin M, Vargas L, Aladwani G, Hindle M Pharm Res. 2025; 42(2):365-384.

PMID: 39930310 PMC: 11880044. DOI: 10.1007/s11095-024-03814-y.

Characterization of Pediatric Extrathoracic Aerosol Deposition with Air-Jet Dry Powder Inhalers.

Thomas M, Bass K, Farkas D, Longest W J Aerosol Sci. 2025; 183.

PMID: 39830599 PMC: 11737425. DOI: 10.1016/j.jaerosci.2024.106474.

Leveraging Numerical Simulation Technology to Advance Drug Preparation: A Comprehensive Review of Application Scenarios and Cases.

Gu Q, Wu H, Sui X, Zhang X, Liu Y, Feng W Pharmaceutics. 2024; 16(10).

PMID: 39458634 PMC: 11511050. DOI: 10.3390/pharmaceutics16101304.

Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies.

Islam N, Suwandecha T, Srichana T Daru. 2024; 32(2):761-779.

PMID: 38861247 PMC: 11555000. DOI: 10.1007/s40199-024-00520-3.

Development of an effective two-equation turbulence modeling approach for simulating aerosol deposition across a range of turbulence levels.

Jubaer H, Thomas M, Farkas D, Kolanjiyil A, Momin M, Hindle M J Aerosol Sci. 2024; 175:106262.

PMID: 38164243 PMC: 10698304. DOI: 10.1016/j.jaerosci.2023.106262.

References

Bass K, Farkas D, Longest W . Optimizing Aerosolization Using Computational Fluid Dynamics in a Pediatric Air-Jet Dry Powder Inhaler. AAPS PharmSciTech. 2019; 20(8):329. PMC: 7324282. DOI: 10.1208/s12249-019-1535-4. View

Longest P, Son Y, Holbrook L, Hindle M . Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols. Pharm Res. 2013; 30(6):1608-27. PMC: 3703624. DOI: 10.1007/s11095-013-1001-z. View

Hindle M, Longest P . Quantitative analysis and design of a spray aerosol inhaler. Part 2: improvements in mouthpiece performance. J Aerosol Med Pulm Drug Deliv. 2012; 26(5):237-47. DOI: 10.1089/jamp.2012.0995. View

Walenga R, Tian G, Hindle M, Yelverton J, Dodson K, Longest P . Variability in Nose-to-Lung Aerosol Delivery. J Aerosol Sci. 2014; 78:11-29. PMC: 4187112. DOI: 10.1016/j.jaerosci.2014.08.003. View

Hansen S, Rau M, Krogh Johansen H, Ciofu O, Jelsbak L, Yang L . Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J. 2011; 6(1):31-45. PMC: 3246239. DOI: 10.1038/ismej.2011.83. View

Moller M, Alanin M, Gronhoj C, Aanaes K, Hoiby N, von Buchwald C . Sinus bacteriology in patients with cystic fibrosis or primary ciliary dyskinesia: A systematic review. Am J Rhinol Allergy. 2017; 31(5):293-298. PMC: 5590177. DOI: 10.2500/ajra.2017.31.4461. View

Wei X, Hindle M, Kaviratna A, Huynh B, Delvadia R, Sandell D . Tests for Aerosol Deposition. VI: Realistic Testing with Different Mouth-Throat Models and Correlations for a Dry Powder Inhaler, Metered Dose Inhaler, and Soft Mist Inhaler. J Aerosol Med Pulm Drug Deliv. 2018; 31(6):358-371. DOI: 10.1089/jamp.2018.1454. View

Lexmond A, Hagedoorn P, Frijlink H, Rottier B, de Boer A . Prerequisites for a dry powder inhaler for children with cystic fibrosis. PLoS One. 2017; 12(8):e0183130. PMC: 5553717. DOI: 10.1371/journal.pone.0183130. View

Longest P, Vinchurkar S . Validating CFD predictions of respiratory aerosol deposition: effects of upstream transition and turbulence. J Biomech. 2006; 40(2):305-16. DOI: 10.1016/j.jbiomech.2006.01.006. View

10.

Linnane B, Kearse L, OConnell N, Fenton J, Kiernan M, Dunne C . A case of failed eradication of cystic fibrosis-related sinus colonisation by Pseudomonas aeruginosa. BMC Pulm Med. 2015; 15:114. PMC: 4596362. DOI: 10.1186/s12890-015-0113-0. View

11.

Bass K, Longest P . Recommendations for Simulating Microparticle Deposition at Conditions Similar to the Upper Airways with Two-Equation Turbulence Models. J Aerosol Sci. 2018; 119:31-50. PMC: 6195318. DOI: 10.1016/j.jaerosci.2018.02.007. View

12.

Walenga R, Longest P . Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs. J Pharm Sci. 2016; 105(1):147-59. PMC: 4746502. DOI: 10.1016/j.xphs.2015.11.027. View

13.

Longest P, Golshahi L, Behara S, Tian G, Farkas D, Hindle M . Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2014; 28(3):189-201. PMC: 4559155. DOI: 10.1089/jamp.2014.1158. View

14.

Longest W, Farkas D, Bass K, Hindle M . Use of Computational Fluid Dynamics (CFD) Dispersion Parameters in the Development of a New DPI Actuated with Low Air Volumes. Pharm Res. 2019; 36(8):110. PMC: 7324281. DOI: 10.1007/s11095-019-2644-1. View

15.

Longest W, Farkas D . Development of a New Inhaler for High-Efficiency Dispersion of Spray-Dried Powders Using Computational Fluid Dynamics (CFD) Modeling. AAPS J. 2019; 21(2):25. PMC: 7276205. DOI: 10.1208/s12248-018-0281-y. View

16.

Coates M, Fletcher D, Chan H, Raper J . Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci. 2004; 93(11):2863-76. DOI: 10.1002/jps.20201. View

17.

Longest P, Vinchurkar S . Effects of mesh style and grid convergence on particle deposition in bifurcating airway models with comparisons to experimental data. Med Eng Phys. 2006; 29(3):350-66. DOI: 10.1016/j.medengphy.2006.05.012. View

18.

Tian G, Hindle M, Lee S, Longest P . Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data. Pharm Res. 2015; 32(10):3170-87. PMC: 4580521. DOI: 10.1007/s11095-015-1695-1. View

19.

Farkas D, Hindle M, Longest P . Application of an inline dry powder inhaler to deliver high dose pharmaceutical aerosols during low flow nasal cannula therapy. Int J Pharm. 2018; 546(1-2):1-9. PMC: 7253153. DOI: 10.1016/j.ijpharm.2018.05.011. View

20.

Coates M, Chan H, Fletcher D, Chiou H . Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res. 2007; 24(8):1450-6. DOI: 10.1007/s11095-007-9262-z. View